Hint mode is switched on Switch off
For swift navigation between sections

NKGen Biotech

PDF download

Choose all Reset all
Download Cancel
Organization name
NKGen Biotech Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

NKGen Biotech is a clinical-stage biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. NKGens product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells with increased activity (defined by parameters such as cytotoxicity, cytokine production and activating receptor expression) as compared to the starting NK cell population.

Awards

News

15/04/2026 NKGen Biotech: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Unregistered Sales Of Equity Securities, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
25/09/2025 NKGen Biotech: Entry Into A Material Definitive Agreement, Financial Statements And Exhibits
04/09/2025 NKGen Biotech: Completion Of Acquisition Or Disposition Of Assets, Regulation Fd Disclosure, Financial Statements And Exhibits
14/07/2025 NKGen Biotech: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
14/05/2025 NKGen Biotech: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001845459
Registration is required to get access.